APA (7th ed.) Citation

Chimalakonda, A., Burke, J., Cheng, L., Catlett, I., Tagen, M., Zhao, Q., . . . Throup, J. (2021). Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatology & Therapy, 11(5), 1763. https://doi.org/10.1007/s13555-021-00596-8

Chicago Style (17th ed.) Citation

Chimalakonda, Anjaneya, et al. "Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors." Dermatology & Therapy 11, no. 5 (2021): 1763. https://doi.org/10.1007/s13555-021-00596-8.

MLA (9th ed.) Citation

Chimalakonda, Anjaneya, et al. "Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors." Dermatology & Therapy, vol. 11, no. 5, 2021, p. 1763, https://doi.org/10.1007/s13555-021-00596-8.